KUALA LUMPUR, Feb 7 (Bernama) -- Keyron, the medical technology (medtech) group focused on reversing type 2 diabetes, non-alcoholic steatohepatitis (NASH) and obesity via an innovative medical device platform, has appointed Carl D Francis as its new Chief Executive Officer (CEO).
In a statement, Keyron said Francis would focus on the reversal of diabetes, NASH and obesity after taking the helm at the medtech group.
Francis said the continuing rise in obesity, diabetes, and all forms of fatty liver disease was one of the biggest health challenges the world faced today, and the numbers continued to rise rapidly.
“Keyron’s technology is a complete game-changer. An innovative, non-surgical, endoscopically-delivered, fully reversible treatment as an alternative to drastic bariatric surgeries is as exciting as it gets. I am really proud and honoured to be part of Keyron.”
Meanwhile, Keyron Chairman, Dr Giorgio Castagneto Gissey said: “We are thrilled that Carl will be leading Keyron as we enter this critical stage of our development as he brings energy, focus, and senior leadership experience to ensure we realise our full potential.
“Keyron has always had high profile, world-leading board members and medical advisers, and we continue to bring onboard remarkable people and are truly delighted to have been able to attract Carl,” he said.
Francis was previously CEO of successful nano-technology group P2i and the group grew from a handful of employees to global leadership in the functional nano-coating space, during his tenure.
He was most recently CEO of United Kingdom-based medtech group Eyoto which specialises in advanced technologies in the optical and ophthalmic industries. Francis started his career as a United States Certified Public Accountant, is a member of Mensa, and has a Bachelor of Science from the University of Cincinnati.
-- BERNAMA
No comments:
Post a Comment